Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

autoimmune disease

- PMLiVE

Nektar Therapeutics announces top-line results from alopecia areata study

This autoimmune disease causes hair loss in both women and men, affecting 160 million people worldwide

- PMLiVE

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology

The expansion builds on the companies’ strategic alliance previously announced in 2021

- PMLiVE

Pfizer’s Litfulo approved by EC for adults and adolescents with severe alopecia areata

The autoimmune disease affects approximately 147 million people globally

- PMLiVE

BioNTech and Ryvu partner to develop immuno-modulatory small molecule candidates

The focus will be on immune modulation within oncology and potentially other disease areas

- PMLiVE

GSK’s new global survey exposes lupus treatment gaps

The findings show opportunities to address organ damage risk for early stage lupus patients

- PMLiVE

Sanofi’s Enjaymo receives EC approval for rare autoimmune haemolytic anaemia

Cold agglutinin disease affects around 12,000 people in the US, Europe and Japan

- PMLiVE

New study links genetic traits of Black Death survivors and autoimmune diseases today

The study involved the extraction and screening of more than 500 ancient DNA samples

- PMLiVE

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos

- PMLiVE

Incyte to acquire Villaris Therapeutics to expand inflammation and autoimmunity portfolio

Auremolimab, which has proven efficacy for vitiligo, is included in the deal

- PMLiVE

Merck to acquire Pandion Therapeutics for $1.85bn

Merck will gain a pipeline of immune modulators targeting autoimmune diseases

- PMLiVE

J&J inks $6.5bn all-cash deal to acquire Momenta

Acquisition sees J&J gain access to portfolio of autoimmune disease treatments

- PMLiVE

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

The five-year deal includes Sitryx’ two lead projects

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links